RxDoctor Payments DataLook up a doctor →

Hessam Aazami, MD

General Practice · Canoga Park, CANPI 1144299173

Payments from drug & device makers

$88,359,317in general payments, 2019–2025

Across 7,972 payments — averaging $11,084 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$59.6M
  • Regeneron$7.8M
  • Pfizer$5.9M
  • Eli Lilly$3.8M
  • AbbVie$1.5M
  • Novartis$1.1M
  • plus $8.6M from 53 others
$628,861in research payments, 2019–2025

Across 37 payments — averaging $16,996 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$569K
  • Eli Lilly$58K
  • Sanofi Pasteur Inc.$2K
  • Regeneron$142

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.5,410$59,576,956
Regeneron78$7,809,325
Pfizer284$5,946,030
Eli Lilly62$3,819,875
AbbVie(2 entities)244$1,451,139
Novartis31$1,122,505
AstraZeneca48$941,219
Partner Therapeutics, Inc.16$931,706
Amgen(2 entities)142$869,106
Intercept Pharmaceuticals, Inc.65$767,287
Boehringer Ingelheim International GmbH220$714,907
Ironwood Pharmaceuticals, Inc50$688,186
Merck26$513,995
Sanofi Pasteur Inc.38$457,617
Ipsen Innovation602$430,474
Sanofi US Services Inc.47$412,171
Pacira Therapeutics, Inc.4$240,666
Sumitomo Pharma America, Inc.98$196,315
Janssen Research & Development, LLC68$186,497
Biohaven Pharmaceutical Holding Company Ltd.38$181,262
Novavax Inc4$153,680
Johnson & Johnson39$142,705
GSK27$129,222
Acadia Pharmaceuticals Inc14$99,864
Bavarian Nordic A/s35$89,861
Myovant Sciences GmbH22$80,431
Boehringer Ingelheim37$74,717
Astrazeneca UK Limited7$65,621
Genentech, Inc.11$55,793
Teva Pharmaceuticals USA, Inc.5$44,839
Adare Pharmaceuticals, Inc.8$39,408
Biogen1$32,779
Boehringer Ingelheim Canada Ltd.ltee34$23,367
Ardelyx, Inc.6$17,163
Lumos Diagnostics, Inc.1$14,600
Romark Laboratories, LC2$13,000
Myovant Sciences Inc.4$8,888
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
Sun Pharmaceutical Industries Inc.1$2,400
Imbrium Therapeutics L.p.1$2,000
Novo Nordisk27$691
Shionogi Inc1$604
Lexicon Pharmaceuticals, Inc.1$588
Boehringer Ingelheim RCV GmbH & Co KG2$540
Sanofi-aventis U.S. LLC27$533
Lilly USA, LLC26$501
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$313
Bayer7$267
Novo Nordisk AS2$256
Amarin Pharma, Inc.11$207
Takeda Pharmaceuticals U.S.A., Inc.7$131
Exact Sciences1$122
Biohaven Pharmaceuticals, Inc.5$107
Astellas Pharma US Inc3$60
Mannkind Corporation1$38
Corcept Therapeutics1$38
Abbott2$35
Nestle Healthcare Nutrition Inc.1$19
Phadia US Inc.1$17

How this compares

$88,359,317 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California →

Medicare billing

Part B allowed, 2024
$160,141
Medicare patients
351
Services billed
2,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other general practice in Canoga Park

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →